Agios Pharmaceuticals, Inc. (0HB0.L)
USD 41.74
(-0.05%)
USD 41.74
(-0.05%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 26.82 Million USD | 88.36% |
| 2022 | 14.24 Million USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | -100.0% |
| 2019 | 117.91 Million USD | 24.92% |
| 2018 | 94.38 Million USD | 119.45% |
| 2017 | 43.01 Million USD | -38.46% |
| 2016 | 69.89 Million USD | 18.22% |
| 2015 | 59.11 Million USD | -9.55% |
| 2014 | 65.35 Million USD | 155.82% |
| 2013 | 25.54 Million USD | 1.76% |
| 2012 | 25.1 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 8.61 Million USD | 5.2% |
| 2024 Q3 | 8.96 Million USD | 4.05% |
| 2024 Q1 | 8.18 Million USD | 15.29% |
| 2023 Q1 | 5.6 Million USD | 30.14% |
| 2023 Q4 | 7.1 Million USD | -4.0% |
| 2023 FY | 26.82 Million USD | 88.36% |
| 2023 Q3 | 7.39 Million USD | 10.24% |
| 2023 Q2 | 6.71 Million USD | 19.66% |
| 2022 Q3 | 3.51 Million USD | -37.01% |
| 2022 FY | 14.24 Million USD | 0.0% |
| 2022 Q4 | 4.31 Million USD | 22.58% |
| 2022 Q2 | 5.58 Million USD | 570.91% |
| 2022 Q1 | 832 Thousand USD | -99.77% |
| 2021 Q1 | - USD | -100.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | 367.34 Million USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 Q4 | 322.77 Million USD | 0.0% |
| 2020 Q1 | - USD | -100.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | - USD | -100.0% |
| 2020 Q3 | - USD | 0.0% |
| 2019 FY | 117.91 Million USD | 24.92% |
| 2019 Q4 | 35.44 Million USD | 36.18% |
| 2019 Q2 | 26.22 Million USD | -13.25% |
| 2019 Q3 | 26.02 Million USD | -0.75% |
| 2019 Q1 | 30.22 Million USD | 0.71% |
| 2018 Q2 | 40.41 Million USD | 361.24% |
| 2018 FY | 94.38 Million USD | 119.45% |
| 2018 Q4 | 30.01 Million USD | 97.48% |
| 2018 Q3 | 15.19 Million USD | -62.39% |
| 2018 Q1 | 8.76 Million USD | -10.58% |
| 2017 Q3 | 11.35 Million USD | 0.11% |
| 2017 Q4 | 9.79 Million USD | -13.73% |
| 2017 FY | 43.01 Million USD | -38.46% |
| 2017 Q1 | 10.5 Million USD | -53.6% |
| 2017 Q2 | 11.34 Million USD | 7.97% |
| 2016 Q1 | 31.28 Million USD | 403.07% |
| 2016 Q2 | 6.97 Million USD | -77.69% |
| 2016 Q3 | 8.98 Million USD | 28.76% |
| 2016 FY | 69.89 Million USD | 18.22% |
| 2016 Q4 | 22.64 Million USD | 152.06% |
| 2015 FY | 59.11 Million USD | -9.55% |
| 2015 Q3 | 5.48 Million USD | -58.54% |
| 2015 Q2 | 13.21 Million USD | -61.35% |
| 2015 Q1 | 34.2 Million USD | 133.68% |
| 2015 Q4 | 6.21 Million USD | 13.47% |
| 2014 Q3 | 33.9 Million USD | 303.04% |
| 2014 FY | 65.35 Million USD | 155.82% |
| 2014 Q4 | 14.63 Million USD | -56.83% |
| 2014 Q1 | 8.41 Million USD | 24.72% |
| 2014 Q2 | 8.41 Million USD | 0.0% |
| 2013 Q4 | 6.74 Million USD | 7.59% |
| 2013 Q1 | 6.26 Million USD | -0.22% |
| 2013 Q2 | 6.26 Million USD | 0.0% |
| 2013 Q3 | 6.26 Million USD | 0.0% |
| 2013 FY | 25.54 Million USD | 1.76% |
| 2012 FY | 25.1 Million USD | 0.0% |
| 2012 Q4 | 6.28 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | 65.666% |
| Dynavax Technologies Corporation | 232.28 Million USD | 88.452% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 95.585% |
| Perrigo Company plc | 4.65 Billion USD | 99.424% |
| Illumina, Inc. | 4.5 Billion USD | 99.404% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.937% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -2155.929% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.982% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 99.821% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 78.887% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.796% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 99.093% |
| Biogen Inc. | 9.83 Billion USD | 99.727% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 84.78% |
| Evolus, Inc. | 202.08 Million USD | 86.727% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -27.924% |
| bluebird bio, Inc. | 29.49 Million USD | 9.065% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 76.943% |
| FibroGen, Inc. | 147.75 Million USD | 81.846% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 99.607% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 503.293% |
| Geron Corporation | 237 Thousand USD | -11217.722% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 98.533% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 93.283% |
| Myriad Genetics, Inc. | 678.4 Million USD | 96.046% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | 26.057% |
| Zoetis Inc. | 8.54 Billion USD | 99.686% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -666.371% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 99.292% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 98.891% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.728% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 96.595% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -212.878% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | 70.237% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 90.088% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 14.164% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 97.843% |
| OPKO Health, Inc. | 863.49 Million USD | 96.894% |
| Exelixis, Inc. | 1.83 Billion USD | 98.534% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 98.579% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 94.439% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -69.305% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | 89.244% |
| Insmed Incorporated | 305.2 Million USD | 91.212% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 96.765% |
| TG Therapeutics, Inc. | 233.66 Million USD | 88.521% |
| Incyte Corporation | 3.69 Billion USD | 99.274% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 97.444% |